gene-silencing drugs
NIH-funded preclinical studies suggest designer drug may treat ALS and spinocerebellar ataxia 2 In two
The first in a new class of gene-silencing drugs, known as inclisiran, has halved cholesterol
NIH-funded preclinical studies suggest designer drug may treat ALS and spinocerebellar ataxia 2 In two
The first in a new class of gene-silencing drugs, known as inclisiran, has halved cholesterol